About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Media Stories

2019 2018 2017 2016 2015

December 2017
1 Dec  U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers
November 2017
23 Nov  Biocon Launches KRABEVA® ­  Biosimilar Bevacizumab for Treating Several Types of  Cancer in India
October 2017
13 Sept  FDA Issues CRL to Mylan and Biocon's  Neulasta Biosimilar
September 2017
20 Sept  Biocon´s Vishakhapatnam API facility  completes US FDA inspection
07 Sept  Biocon's insulin facility in Malaysia clears  inspections for European market
August 2017
31 Aug  Trastuzumab commercialisation on track,   Biocon says after USFDA extends  review deadline by 3 months
16 Aug  #MakeInIndia – Kiran Mazumdar-Shaw
July 2017
31 Jul  Mazumdar Shaw: We are seeing a recovery in  the second quarter
21 Jul  Biocon Featured in ´Outlook Business    Outperformers´ special edition
17 Jul  It's Biocon's day in the sun
14 Jul  Biocon–Mylan´s Breast Cancer Biosimilar Cancer biosimilar gets Thumbs-up from USFDAs Oncologic Drugs Advisiory Committee
15 Jul  US FDA Panel Nod for Biocon Breast Cancer Drug Biosimilar
May 2017
8 May  'We need a system which provides quality drugs at low cost' Interview with Ms. Shaw
5 May  US institute honours Kiran with award for excellence
April 2017
28 Apr  Biocon set to issue bonus shares 2:1;  revenue flat in Q4
28 Apr  Biocon Q4 profits up 75% to Rs 135-Cr
March 2017
27 Mar  Our biologics business is expected to  continue on its strong growth trajectory
17 Mar  For Biocon, Windfall seen from drug launch
08 Mar  Biocon’s strong positioning in the area of  Biosimilars and robust pipeline.
01 Mar  Healing The World
February 2017
16 Feb  USFDA accepts Biocon's drug application for  review
02 Feb  We expect Malaysia unit to break even next  year
January 2017
31 Jan  Biocon Limited: Strong quarter, positive  trends
30 Jan  Tech based patient tracking to make its  debut in state
30 Jan  Biocon aims for the highest quality in the  lowest cost
27 Jan  Biocon Q3:all eyes on pot at the end of  rainbow
26 Jan  'We expect a turnaround in branded  formulations in FY18'
26 Jan  Biocon bags Rs 460-cr contract from  Malaysia
17 Jan  In Biocon, investors sees a blockbuster  pipeline
14 Jan  Biocon a leading Indian play on global  biosimilar scene
13 Jan  Market opportunity for trastuzumab is $7  billion
05 Jan  Biocon has little room to slip up after strong  2016
05 Jan  These graduates aim to take Biotech to  another level





Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved